About Tempus AI, Inc. - Class A Common Stock (TEM)
Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More
Law Offices of Howard G. Smith reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”).
NEW ORLEANS, June 25, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. The study, “Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer,” demonstrated that the CARE program accurately interprets NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1,2 with 99.5% accuracy, reinforcing its effectiveness as a digital risk assessment tool for identifying patients who may benefit from hereditary cancer-focused genetic testing and personalized care.
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion.
NEW YORK, NY AND NEW ORLEANS, LA / ACCESS Newswire / June 23, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion.
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). Tempus investors have until August 12, 2025 to file a lead plaintiff motion.
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors concerning the Company’s possible violations of the federal securities laws.
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.
Law Offices of Howard G. Smith announces an investigation on behalf of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) investors concerning the Company’s possible violations of federal securities laws.
NEW YORK CITY AND NEW ORLEANS / ACCESS Newswire / June 19, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS:TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Eastern District of Illinois on behalf of investors (the “Class”) who purchased or acquired the common stock of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) between August 6, 2024 and May 27, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers (the “Complaint”).
NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
The Law Offices of Frank R. Cruz announces an investigation of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of investors concerning the Company’s possible violations of federal securities laws.
NEW YORK and NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx Revolution conference. The event is taking place on June 22 - 25, 2025, in Dana Point, California. Jim Rogers, Chief Financial Officer of Tempus, will join the panel “Acing AI – How To Play The Platforms” on June 23.
TEMPUS AI (NASDAQ:TEM) is a high-growth healthcare tech stock meeting Minervini's Trend Template with strong revenue growth, earnings beats, and a perfect technical rating of 10/10.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
